TB-500 Research Guide: Mechanism, Studies & Reconstitution Protocol

TB-500 is a synthetic peptide derived from Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid protein found in virtually all human and animal cells. First isolated from the thymus gland in the 1960s, Thymosin Beta-4 has been the subject of extensive research for its roles in actin sequestration, cell migration, angiogenesis, and tissue remodeling. TB-500 represents the active fragment of this protein — specifically the actin-binding domain — that researchers believe is responsible for the majority of its biological activity.

For research use only. Not intended for human or veterinary use.

What Is TB-500?

TB-500 corresponds to amino acids 17–23 of the full Thymosin Beta-4 sequence (Ac-LKKTETQ). This short peptide fragment retains the actin-binding domain of the full protein and has demonstrated similar biological properties in cell culture and animal research models. Unlike the full 43-amino acid chain, TB-500’s shorter length makes it more amenable to synthetic production and more stable in solution.

In research contexts, TB-500 is typically studied for its effects on:

• Cell migration and proliferation in wound healing models
• Angiogenesis (formation of new blood vessels)
• Modulation of inflammation in tissue injury models
• Cardiac and skeletal muscle repair in preclinical studies
• Neurogenesis in models of central nervous system injury

Mechanism of Action

Actin Sequestration and Cell Motility

The primary mechanism of Thymosin Beta-4 (and by extension TB-500) involves binding to G-actin (monomeric actin) and regulating its polymerization into F-actin filaments. This actin-sequestering activity is central to cell motility — the ability of cells to migrate toward sites of injury or tissue damage.

In wound-healing research, cell migration is a prerequisite for tissue repair. Keratinocytes, endothelial cells, and fibroblasts must migrate to the wound site, and disruption of actin polymerization dynamics impairs this process. Research suggests Tβ4/TB-500 facilitates this migration by maintaining the pool of available G-actin needed for lamellipodia formation at the leading edge of migrating cells.

Angiogenic Effects

Multiple in vitro and in vivo studies have demonstrated that Tβ4 promotes angiogenesis — the sprouting of new capillaries from existing vasculature. This is thought to occur via upregulation of vascular endothelial growth factor (VEGF) and activation of integrin-linked kinase (ILK), a key mediator of endothelial cell survival and migration.

In ischemia research models, treatment with Tβ4 has been associated with increased capillary density and improved blood flow in ischemic tissue, supporting its investigation as a potential tool in cardiovascular research.

Anti-Inflammatory Signaling

Tβ4 has demonstrated the ability to downregulate NF-κB signaling — a master transcription factor controlling pro-inflammatory gene expression — in several cell-based studies. This effect may partially account for observations of reduced inflammatory infiltration in tissue injury models treated with the peptide. Additionally, Tβ4 has been shown to promote expression of anti-inflammatory cytokines while suppressing TNF-α and IL-1β in some experimental contexts.

Key Research Findings

Wound Healing and Tissue Repair

Goldstein et al. (2012) demonstrated that topical application of Tβ4 significantly accelerated wound closure in full-thickness dermal wound models, associated with increased keratinocyte migration and collagen deposition. Earlier work by Malinda et al. (1999) showed that Tβ4 administered at wound sites in rodents resulted in significantly faster re-epithelialization compared to controls.

These findings established the biological plausibility for TB-500’s continued investigation in tissue repair research and served as the basis for RegeneRx Biopharmaceuticals’ clinical development of Tβ4-based compounds (RGN-137, RGN-259) for corneal and dermal wound applications.

Cardiac Research

Bock-Marquette et al. (2004), publishing in Nature, reported that Tβ4 treatment activated ILK in cardiac progenitor cells and significantly improved cardiac function in mouse models of myocardial infarction. Treated animals showed increased cardiomyocyte survival and reduced scar formation post-infarction — findings that generated substantial interest in Tβ4 as a subject for cardiac regeneration research.

Subsequent work by Smart et al. (2007) identified that Tβ4 treatment could reactivate dormant epicardial progenitor cells and stimulate their differentiation into cardiomyocytes and smooth muscle cells — a significant finding in the context of cardiac regeneration research.

Neurological Research

Research by Xiong et al. (2011) in animal models of traumatic brain injury demonstrated that Tβ4 treatment was associated with improved neurological function, increased neurogenesis in the hippocampus, and reduced lesion volume. The proposed mechanism involved angiogenesis and oligodendrogenesis — the generation of myelin-producing cells — in regions adjacent to the injury site.

Fibrosis and Liver Research

Several studies have examined Tβ4’s role in hepatic fibrosis models. Reeves et al. (2013) found that Tβ4 treatment reduced hepatic stellate cell activation and collagen deposition in murine fibrosis models, suggesting potential as a research tool for studying fibrosis mechanisms.

TB-500 vs. Thymosin Beta-4: What’s the Difference?

A common point of confusion in research literature is the interchangeable use of “TB-500” and “Thymosin Beta-4.” They are related but distinct:

• Thymosin Beta-4 (Tβ4): Full 43-amino acid protein, naturally produced endogenously; the complete molecule used in most published research and clinical trials
• TB-500: Synthetic peptide corresponding to the active fragment (aa 17–23: Ac-LKKTETQ); more stable, easier to synthesize, and commonly used in preclinical research as a proxy for full Tβ4 activity

Most mechanistic research has been conducted using full-length Tβ4. Whether the shortened TB-500 fragment fully recapitulates all biological effects of the complete protein remains an open question in the literature.

Reconstitution Protocol

TB-500 is supplied as a lyophilized (freeze-dried) white powder and requires reconstitution with bacteriostatic water before use in research applications.

Standard Reconstitution

• Add bacteriostatic water slowly to the inner wall of the vial — do not inject directly onto the powder
• Gently swirl to dissolve — do not shake
• Allow 1–2 minutes for complete dissolution; the solution should be clear and colorless
• Common research concentrations: 2 mg/mL (add 2.5 mL BAC water to a 5 mg vial) or 5 mg/mL (add 1 mL BAC water)

Storage After Reconstitution

• Refrigerate at 2–8°C — reconstituted TB-500 is stable for approximately 4–6 weeks under refrigeration
• Protect from light — store in the original amber vial or cover with foil
• Do not freeze reconstituted solution — lyophilized (dry) TB-500 can be stored at -20°C long term, but reconstituted solution should not be frozen

For detailed reconstitution instructions, see our comprehensive guide: How to Reconstitute Research Peptides: A Complete Guide.

Purity and Quality Considerations

For research purposes, peptide purity is a critical variable. TB-500 used in cell-based or animal studies should be verified by HPLC (high-performance liquid chromatography) and mass spectrometry to confirm sequence accuracy and rule out impurities that could confound experimental results. Researchers should request and review certificates of analysis (CoA) from suppliers confirming purity levels — typically ≥98% for research-grade applications.

References

• Bock-Marquette, I., Saxena, A., White, M. D., Dimaio, J. M., & Srivastava, D. (2004). Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 432(7016), 466–472. https://doi.org/10.1038/nature03000
• Goldstein, A. L., Hannappel, E., Sosne, G., & Kleinman, H. K. (2012). Thymosin β4: A multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37–51.
• Malinda, K. M., Sidhu, G. S., Mani, H., Banaudha, K., Maheshwari, R. K., Goldstein, A. L., & Kleinman, H. K. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 113(3), 364–368.
• Smart, N., Risebro, C. A., Melville, A. A. D., Moses, K., Schwartz, R. J., Bhatt, D. L., … & Riley, P. R. (2007). Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445(7124), 177–182.
• Xiong, Y., Mahmood, A., Meng, Y., Zhang, Y., Zhang, Z. G., Morris, D. C., & Chopp, M. (2011). Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Annals of the New York Academy of Sciences, 1270(1), 51–58.
• Reeves, H. L., Burt, A. D., Wood, S., & Day, C. P. (2013). Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. Journal of Hepatology [related Tβ4/fibrosis research].

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.